Details on FDA approval of Pegcetacoplan-Empaveli

Pegcetacoplan is byApellis An innovative therapeutic developed by Pharmaceuticals has been approved by the U.S. Food and Drug Administration (FDA) for the treatment of adult patients with paroxysmal nocturnal hemoglobinuria (PNH) and is effective in the treatment of adult and pediatric patients 12 years of age and older with C3 glomerulopathy (C3G) or primary immune complex membrane proliferative glomerulonephritis (IC-MPGN). Empaveli regulates the over-activated complement cascade by targeting complement C3, and has shown important efficacy in the treatment of diseases such as PNH, C3G and IC-MPGN.

PNH is a rare, chronic and fatal blood disease characterized by intravascular and extravascular hemolysis, leading to the destruction of red blood cells, which in turn leads to anemia, fatigue, dyspnea and other symptoms. People with PNH often have low hemoglobin levels and require frequent blood transfusions. Treatment of the disease focuses on slowing the hemolytic reaction, increasing hemoglobin levels, and improving the patient's overall health.

C3G and IC-MPGN are rare and fatal kidney diseases in which patients often develop renal failure due to excessive C3 protein deposition in the kidneys. A common feature of these diseases is abnormal activation of the complement system, leading to chronic inflammation, damage, and eventual failure of the kidneys. Empaveli inhibits the complement cascade by binding to complement protein C3 and its activating fragment C3b, thereby alleviating the symptoms of such diseases and preventing further kidney damage.

Empaveli is currently the only therapy targeting C3, and its unique mechanism gives it significant advantages in the treatment of these complex immune diseases. Empaveli is administered by subcutaneous injection twice weekly into patients using a commercially available infusion pump or Empaveli syringe.

Reference materials:https://empaveli.com/